#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-7	Alcohol	_
1-2	8-15	effects	_
1-3	16-18	on	_
1-4	19-25	globus	_
1-5	26-34	pallidus	_
1-6	35-47	connectivity	_
1-7	48-49	:	_
1-8	50-54	Role	_
1-9	55-57	of	_
1-10	58-69	impulsivity	_
1-11	70-73	and	_
1-12	74-79	binge	_
1-13	80-88	drinking	_
1-14	89-96	Despite	_
1-15	97-100	the	_
1-16	101-105	harm	_
1-17	106-112	caused	_
1-18	113-115	by	_
1-19	116-121	binge	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingBinge
1-20	122-130	drinking	_
1-21	131-132	,	_
1-22	133-136	the	_
1-23	137-143	neural	_
1-24	144-154	mechanisms	_
1-25	155-162	leading	_
1-26	163-165	to	_
1-27	166-171	risky	_
1-28	172-175	and	_
1-29	176-188	disinhibited	_
1-30	189-209	intoxication-related	_
1-31	210-219	behaviors	_
1-32	220-223	are	_
1-33	224-227	not	_
1-34	228-232	well	_
1-35	233-243	understood	_
1-36	244-245	.	_

2-1	246-254	Evidence	_
2-2	255-263	suggests	_
2-3	264-268	that	_
2-4	269-272	the	_
2-5	273-279	globus	_
2-6	280-288	pallidus	_
2-7	289-297	externus	_
2-8	298-299	(	_
2-9	300-303	GPe	_
2-10	304-305	)	_
2-11	306-307	,	_
2-12	308-309	a	_
2-13	310-322	substructure	_
2-14	323-329	within	_
2-15	330-333	the	_
2-16	334-339	basal	_
2-17	340-347	ganglia	_
2-18	348-349	,	_
2-19	350-362	participates	_
2-20	363-365	in	_
2-21	366-376	inhibitory	_
2-22	377-384	control	_
2-23	385-394	processes	_
2-24	395-396	,	_
2-25	397-399	as	_
2-26	400-408	examined	_
2-27	409-411	in	_
2-28	412-426	stop-signaling	_
2-29	427-432	tasks	_
2-30	433-434	.	_

3-1	435-437	In	_
3-2	438-442	fact	_
3-3	443-444	,	_
3-4	445-452	studies	_
3-5	453-455	in	_
3-6	456-463	rodents	_
3-7	464-468	have	_
3-8	469-477	revealed	_
3-9	478-482	that	_
3-10	483-490	alcohol	_
3-11	491-494	can	_
3-12	495-501	change	_
3-13	502-505	GPe	_
3-14	506-514	activity	_
3-15	515-517	by	_
3-16	518-528	decreasing	_
3-17	529-537	neuronal	_
3-18	538-544	firing	_
3-19	545-550	rates	_
3-20	551-552	,	_
3-21	553-563	suggesting	_
3-22	564-568	that	_
3-23	569-572	the	_
3-24	573-576	GPe	_
3-25	577-580	may	_
3-26	581-585	have	_
3-27	586-587	a	_
3-28	588-595	central	_
3-29	596-600	role	_
3-30	601-603	in	_
3-31	604-614	explaining	_
3-32	615-624	impulsive	_
3-33	625-634	behaviors	_
3-34	635-638	and	_
3-35	639-647	failures	_
3-36	648-650	of	_
3-37	651-661	inhibition	_
3-38	662-666	that	_
3-39	667-672	occur	_
3-40	673-679	during	_
3-41	680-685	binge	_
3-42	686-694	drinking	_
3-43	695-696	.	_

4-1	697-699	In	_
4-2	700-704	this	_
4-3	705-710	study	_
4-4	711-712	,	_
4-5	713-724	twenty-five	_
4-6	725-732	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
4-7	733-743	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
4-8	744-753	underwent	_
4-9	754-765	intravenous	_
4-10	766-773	alcohol	_
4-11	774-782	infusion	_
4-12	783-785	to	_
4-13	786-793	achieve	_
4-14	794-795	a	_
4-15	796-801	blood	_
4-16	802-809	alcohol	_
4-17	810-815	level	_
4-18	816-818	of	_
4-19	819-823	0.08	_
4-20	824-828	g/dl	_
4-21	829-830	,	_
4-22	831-836	which	_
4-23	837-839	is	_
4-24	840-850	equivalent	_
4-25	851-853	to	_
4-26	854-855	a	_
4-27	856-861	binge	_
4-28	862-870	drinking	_
4-29	871-878	episode	_
4-30	879-880	.	_

5-1	881-882	A	_
5-2	883-890	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
5-3	891-896	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
5-4	897-907	functional	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
5-5	908-916	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
5-6	917-926	resonance	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
5-7	927-934	imaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
5-8	935-939	scan	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
5-9	940-943	was	_
5-10	944-953	collected	_
5-11	954-959	prior	_
5-12	960-962	to	_
5-13	963-966	the	_
5-14	967-975	infusion	_
5-15	976-979	and	_
5-16	980-982	at	_
5-17	983-994	binge-level	_
5-18	995-1003	exposure	_
5-19	1004-1005	.	_

6-1	1006-1016	Functional	_
6-2	1017-1029	connectivity	_
6-3	1030-1038	analysis	_
6-4	1039-1042	was	_
6-5	1043-1047	used	_
6-6	1048-1050	to	_
6-7	1051-1062	investigate	_
6-8	1063-1066	the	_
6-9	1067-1078	association	_
6-10	1079-1086	between	_
6-11	1087-1102	alcohol-induced	_
6-12	1103-1110	changes	_
6-13	1111-1113	in	_
6-14	1114-1117	GPe	_
6-15	1118-1130	connectivity	_
6-16	1131-1132	,	_
6-17	1133-1141	drinking	_
6-18	1142-1151	behaviors	_
6-19	1152-1153	,	_
6-20	1154-1157	and	_
6-21	1158-1169	impulsivity	_
6-22	1170-1176	traits	_
6-23	1177-1178	.	_

7-1	1179-1181	We	_
7-2	1182-1187	found	_
7-3	1188-1192	that	_
7-4	1193-1204	individuals	_
7-5	1205-1209	with	_
7-6	1210-1217	greater	_
7-7	1218-1224	number	_
7-8	1225-1227	of	_
7-9	1228-1234	drinks	_
7-10	1235-1237	or	_
7-11	1238-1243	heavy	_
7-12	1244-1252	drinking	_
7-13	1253-1257	days	_
7-14	1258-1260	in	_
7-15	1261-1264	the	_
7-16	1265-1271	recent	_
7-17	1272-1276	past	_
7-18	1277-1280	had	_
7-19	1281-1288	greater	_
7-20	1289-1304	alcohol-induced	_
7-21	1305-1313	deficits	_
7-22	1314-1316	in	_
7-23	1317-1320	GPe	_
7-24	1321-1333	connectivity	_
7-25	1334-1335	,	_
7-26	1336-1348	particularly	_
7-27	1349-1351	to	_
7-28	1352-1355	the	_
7-29	1356-1364	striatum	_
7-30	1365-1366	.	_

8-1	1367-1370	Our	_
8-2	1371-1375	data	_
8-3	1376-1380	also	_
8-4	1381-1390	indicated	_
8-5	1391-1393	an	_
8-6	1394-1405	association	_
8-7	1406-1413	between	_
8-8	1414-1425	impulsivity	_
8-9	1426-1429	and	_
8-10	1430-1445	alcohol-induced	_
8-11	1446-1454	deficits	_
8-12	1455-1457	in	_
8-13	1458-1480	GPe—frontal/precentral	_
8-14	1481-1493	connectivity	_
8-15	1494-1495	.	_

9-1	1496-1504	Moreover	_
9-2	1505-1506	,	_
9-3	1507-1514	alcohol	_
9-4	1515-1522	induced	_
9-5	1523-1530	changes	_
9-6	1531-1533	in	_
9-7	1534-1546	GPe-amygdala	_
9-8	1547-1556	circuitry	_
9-9	1557-1566	suggested	_
9-10	1567-1574	greater	_
9-11	1575-1590	vulnerabilities	_
9-12	1591-1593	to	_
9-13	1594-1608	stress-related	_
9-14	1609-1617	drinking	_
9-15	1618-1620	in	_
9-16	1621-1625	some	_
9-17	1626-1637	individuals	_
9-18	1638-1639	.	_

10-1	1640-1645	Taken	_
10-2	1646-1654	together	_
10-3	1655-1656	,	_
10-4	1657-1662	these	_
10-5	1663-1671	findings	_
10-6	1672-1679	suggest	_
10-7	1680-1684	that	_
10-8	1685-1692	alcohol	_
10-9	1693-1696	may	_
10-10	1697-1705	interact	_
10-11	1706-1710	with	_
10-12	1711-1720	impulsive	_
10-13	1721-1732	personality	_
10-14	1733-1739	traits	_
10-15	1740-1743	and	_
10-16	1744-1752	drinking	_
10-17	1753-1761	patterns	_
10-18	1762-1764	to	_
10-19	1765-1770	drive	_
10-20	1771-1782	alterations	_
10-21	1783-1785	in	_
10-22	1786-1789	GPe	_
10-23	1790-1799	circuitry	_
10-24	1800-1810	associated	_
10-25	1811-1815	with	_
10-26	1816-1826	behavioral	_
10-27	1827-1837	inhibition	_
10-28	1838-1839	,	_
10-29	1840-1848	possibly	_
10-30	1849-1859	indicating	_
10-31	1860-1861	a	_
10-32	1862-1868	neural	_
10-33	1869-1878	mechanism	_
10-34	1879-1881	by	_
10-35	1882-1887	which	_
10-36	1888-1893	binge	_
10-37	1894-1902	drinking	_
10-38	1903-1908	could	_
10-39	1909-1913	lead	_
10-40	1914-1916	to	_
10-41	1917-1926	impulsive	_
10-42	1927-1936	behaviors	_
10-43	1937-1938	.	_

11-1	1939-1946	Methods	_
11-2	1947-1951	This	_
11-3	1952-1957	study	_
11-4	1958-1961	was	_
11-5	1962-1970	approved	_
11-6	1971-1973	by	_
11-7	1974-1977	the	_
11-8	1978-1981	NIH	_
11-9	1982-1992	Addictions	_
11-10	1993-2006	Institutional	_
11-11	2007-2013	Review	_
11-12	2014-2019	Board	_
11-13	2020-2025	under	_
11-14	2026-2036	12-AA-0032	_
11-15	2037-2038	.	_

12-1	2039-2042	All	_
12-2	2043-2051	subjects	_
12-3	2052-2060	provided	_
12-4	2061-2068	written	_
12-5	2069-2077	informed	_
12-6	2078-2085	consent	_
12-7	2086-2091	prior	_
12-8	2092-2094	to	_
12-9	2095-2100	their	_
12-10	2101-2114	participation	_
12-11	2115-2117	in	_
12-12	2118-2121	the	_
12-13	2122-2127	study	_
12-14	2128-2129	.	_

13-1	2130-2142	Participants	_
13-2	2143-2154	Twenty-five	_
13-3	2155-2162	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
13-4	2163-2164	(	_
13-5	2165-2167	13	_
13-6	2168-2173	males	_
13-7	2174-2175	,	_
13-8	2176-2178	12	_
13-9	2179-2186	females	_
13-10	2187-2188	;	_
13-11	2189-2193	mean	_
13-12	2194-2197	age	_
13-13	2198-2199	:	_
13-14	2200-2205	28.85	_
13-15	2206-2211	years	_
13-16	2212-2213	)	_
13-17	2214-2215	,	_
13-18	2216-2221	light	http://maven.renci.org/NeuroBridge/neurobridge#TheSocialFunctionQuestionnaire
13-19	2222-2228	social	http://maven.renci.org/NeuroBridge/neurobridge#TheSocialFunctionQuestionnaire
13-20	2229-2237	drinkers	http://maven.renci.org/NeuroBridge/neurobridge#TheSocialFunctionQuestionnaire
13-21	2238-2242	were	_
13-22	2243-2252	recruited	_
13-23	2253-2255	by	_
13-24	2256-2261	local	_
13-25	2262-2275	advertisement	_
13-26	2276-2277	,	_
13-27	2278-2287	according	_
13-28	2288-2290	to	_
13-29	2291-2299	approved	_
13-30	2300-2308	National	_
13-31	2309-2319	Institutes	_
13-32	2320-2322	of	_
13-33	2323-2329	Health	_
13-34	2330-2343	Institutional	_
13-35	2344-2350	Review	_
13-36	2351-2356	Board	_
13-37	2357-2367	procedures	_
13-38	2368-2369	.	_

14-1	2370-2373	The	_
14-2	2374-2385	demographic	_
14-3	2386-2390	data	_
14-4	2391-2393	of	_
14-5	2394-2406	participants	_
14-6	2407-2409	is	_
14-7	2410-2420	summarized	_
14-8	2421-2423	in	_
14-9	2424-2429	Table	_
14-10	2430-2431	1	_
14-11	2432-2433	.	_

15-1	2434-2439	After	_
15-2	2440-2449	obtaining	_
15-3	2450-2457	written	_
15-4	2458-2466	informed	_
15-5	2467-2474	consent	_
15-6	2475-2476	,	_
15-7	2477-2480	all	_
15-8	2481-2493	participants	_
15-9	2494-2503	underwent	_
15-10	2504-2505	a	_
15-11	2506-2519	comprehensive	_
15-12	2520-2527	medical	_
15-13	2528-2534	screen	_
15-14	2535-2536	,	_
15-15	2537-2546	including	_
15-16	2547-2552	blood	_
15-17	2553-2557	work	_
15-18	2558-2559	,	_
15-19	2560-2570	urinalysis	_
15-20	2571-2572	,	_
15-21	2573-2580	medical	_
15-22	2581-2588	history	_
15-23	2589-2590	,	_
15-24	2591-2599	physical	_
15-25	2600-2604	exam	_
15-26	2605-2606	,	_
15-27	2607-2610	and	_
15-28	2611-2612	a	_
15-29	2613-2623	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
15-30	2624-2632	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
15-31	2633-2642	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
15-32	2643-2646	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
15-33	2647-2650	the	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
15-34	2651-2654	DSM	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
15-35	2655-2661	Axis-I	_
15-36	2662-2671	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#MoodDisorder
15-37	2672-2673	(	http://maven.renci.org/NeuroBridge/neurobridge#MoodDisorder
15-38	2674-2681	SCID-IV	http://maven.renci.org/NeuroBridge/neurobridge#MoodDisorder
15-39	2682-2683	)	http://maven.renci.org/NeuroBridge/neurobridge#MoodDisorder
15-40	2684-2685	.	_

16-1	2686-2694	Criteria	_
16-2	2695-2698	for	_
16-3	2699-2708	inclusion	_
16-4	2709-2711	in	_
16-5	2712-2716	this	_
16-6	2717-2722	study	_
16-7	2723-2727	were	_
16-8	2728-2729	:	_
16-9	2730-2737	healthy	_
16-10	2738-2739	,	_
16-11	2740-2745	21–45	_
16-12	2746-2751	years	_
16-13	2752-2755	old	_
16-14	2756-2757	,	_
16-15	2758-2769	consumption	_
16-16	2770-2772	of	_
16-17	2773-2774	1	_
16-18	2775-2777	to	_
16-19	2778-2780	10	_
16-20	2781-2787	drinks	_
16-21	2788-2791	per	_
16-22	2792-2796	week	_
16-23	2797-2800	for	_
16-24	2801-2808	females	_
16-25	2809-2812	and	_
16-26	2813-2814	1	_
16-27	2815-2817	to	_
16-28	2818-2820	14	_
16-29	2821-2827	drinks	_
16-30	2828-2831	per	_
16-31	2832-2836	week	_
16-32	2837-2840	for	_
16-33	2841-2846	males	_
16-34	2847-2848	.	_

17-1	2849-2857	Subjects	_
17-2	2858-2862	also	_
17-3	2863-2866	had	_
17-4	2867-2869	to	_
17-5	2870-2874	have	_
17-6	2875-2883	consumed	_
17-7	2884-2886	at	_
17-8	2887-2892	least	_
17-9	2893-2896	two	_
17-10	2897-2905	standard	_
17-11	2906-2912	drinks	_
17-12	2913-2915	of	_
17-13	2916-2923	alcohol	_
17-14	2924-2930	within	_
17-15	2931-2934	one	_
17-16	2935-2939	hour	_
17-17	2940-2942	on	_
17-18	2943-2945	at	_
17-19	2946-2951	least	_
17-20	2952-2955	one	_
17-21	2956-2964	occasion	_
17-22	2965-2967	in	_
17-23	2968-2973	their	_
17-24	2974-2982	lifetime	_
17-25	2983-2984	.	_

18-1	2985-2993	Criteria	_
18-2	2994-2997	for	_
18-3	2998-3007	exclusion	_
18-4	3008-3016	included	_
18-5	3017-3018	:	_
18-6	3019-3027	abnormal	_
18-7	3028-3033	blood	_
18-8	3034-3036	or	_
18-9	3037-3042	urine	_
18-10	3043-3046	lab	_
18-11	3047-3051	test	_
18-12	3052-3058	values	_
18-13	3059-3061	or	_
18-14	3062-3070	findings	_
18-15	3071-3075	from	_
18-16	3076-3079	the	_
18-17	3080-3087	medical	_
18-18	3088-3094	screen	_
18-19	3095-3096	,	_
18-20	3097-3103	DSM-IV	_
18-21	3104-3112	criteria	_
18-22	3113-3116	for	_
18-23	3117-3124	alcohol	_
18-24	3125-3127	or	_
18-25	3128-3133	other	_
18-26	3134-3143	substance	_
18-27	3144-3154	dependence	_
18-28	3155-3156	(	_
18-29	3157-3166	excluding	_
18-30	3167-3175	nicotine	_
18-31	3176-3177	)	_
18-32	3178-3180	at	_
18-33	3181-3184	any	_
18-34	3185-3189	time	_
18-35	3190-3191	;	_
18-36	3192-3199	current	_
18-37	3200-3202	or	_
18-38	3203-3207	past	_
18-39	3208-3213	major	_
18-40	3214-3225	psychiatric	_
18-41	3226-3234	disorder	_
18-42	3235-3236	(	_
18-43	3237-3243	DSM-IV	_
18-44	3244-3248	Axis	_
18-45	3249-3250	I	_
18-46	3251-3252	)	_
18-47	3253-3254	,	_
18-48	3255-3259	head	_
18-49	3260-3266	injury	_
18-50	3267-3276	requiring	_
18-51	3277-3292	hospitalization	_
18-52	3293-3294	,	_
18-53	3295-3299	Body	_
18-54	3300-3304	Mass	_
18-55	3305-3310	Index	_
18-56	3311-3312	(	_
18-57	3313-3316	BMI	_
18-58	3317-3318	)	_
18-59	3319-3324	value	_
18-60	3325-3329	over	_
18-61	3330-3332	30	_
18-62	3333-3334	,	_
18-63	3335-3344	inability	_
18-64	3345-3347	to	_
18-65	3348-3352	stop	_
18-66	3353-3359	taking	_
18-67	3360-3363	any	_
18-68	3364-3374	medication	_
18-69	3375-3377	or	_
18-70	3378-3383	drugs	_
18-71	3384-3385	3	_
18-72	3386-3390	days	_
18-73	3391-3396	prior	_
18-74	3397-3399	to	_
18-75	3400-3405	study	_
18-76	3406-3410	days	_
18-77	3411-3412	,	_
18-78	3413-3416	and	_
18-79	3417-3420	MRI	_
18-80	3421-3438	contraindications	_
18-81	3439-3440	.	_

19-1	3441-3445	Also	_
19-2	3446-3447	,	_
19-3	3448-3460	non-drinkers	_
19-4	3461-3465	were	_
19-5	3466-3474	excluded	_
19-6	3475-3479	from	_
19-7	3480-3483	the	_
19-8	3484-3489	study	_
19-9	3490-3493	due	_
19-10	3494-3496	to	_
19-11	3497-3504	ethical	_
19-12	3505-3513	concerns	_
19-13	3514-3521	related	_
19-14	3522-3524	to	_
19-15	3525-3532	alcohol	_
19-16	3533-3547	administration	_
19-17	3548-3549	.	_

20-1	3550-3558	Measures	_
20-2	3559-3566	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
20-3	3567-3575	drinking	_
20-4	3576-3584	measures	_
20-5	3585-3588	The	_
20-6	3589-3595	amount	_
20-7	3596-3598	of	_
20-8	3599-3604	daily	_
20-9	3605-3612	alcohol	_
20-10	3613-3624	consumption	_
20-11	3625-3629	over	_
20-12	3630-3633	the	_
20-13	3634-3638	last	_
20-14	3639-3641	90	_
20-15	3642-3646	days	_
20-16	3647-3650	was	_
20-17	3651-3659	measured	_
20-18	3660-3665	using	_
20-19	3666-3669	the	_
20-20	3670-3677	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseScale
20-21	3678-3697	Timeline-Followback	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseScale
20-22	3698-3699	(	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseScale
20-23	3700-3704	TLFB	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseScale
20-24	3705-3706	)	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseScale
20-25	3707-3717	calendar—a	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseScale
20-26	3718-3726	drinking	_
20-27	3727-3737	assessment	_
20-28	3738-3744	method	_
20-29	3745-3749	with	_
20-30	3750-3754	good	_
20-31	3755-3767	psychometric	_
20-32	3768-3783	characteristics	_
20-33	3784-3787	for	_
20-34	3788-3798	estimating	_
20-35	3799-3812	retrospective	_
20-36	3813-3818	daily	_
20-37	3819-3827	drinking	_
20-38	3828-3836	patterns	_
20-39	3837-3838	.	_

21-1	3839-3842	The	_
21-2	3843-3849	number	_
21-3	3850-3852	of	_
21-4	3853-3858	heavy	_
21-5	3859-3867	drinking	_
21-6	3868-3872	days	_
21-7	3873-3875	in	_
21-8	3876-3879	the	_
21-9	3880-3884	last	_
21-10	3885-3887	90	_
21-11	3888-3892	days	_
21-12	3893-3896	was	_
21-13	3897-3907	calculated	_
21-14	3908-3912	from	_
21-15	3913-3916	the	_
21-16	3917-3921	TLFB	_
21-17	3922-3923	;	_
21-18	3924-3925	a	_
21-19	3926-3931	heavy	_
21-20	3932-3940	drinking	_
21-21	3941-3944	day	_
21-22	3945-3947	is	_
21-23	3948-3955	defined	_
21-24	3956-3958	as	_
21-25	3959-3960	4	_
21-26	3961-3963	or	_
21-27	3964-3968	more	_
21-28	3969-3975	drinks	_
21-29	3976-3979	per	_
21-30	3980-3983	day	_
21-31	3984-3987	for	_
21-32	3988-3993	women	_
21-33	3994-3997	and	_
21-34	3998-3999	5	_
21-35	4000-4002	or	_
21-36	4003-4007	more	_
21-37	4008-4014	drinks	_
21-38	4015-4018	per	_
21-39	4019-4022	day	_
21-40	4023-4026	for	_
21-41	4027-4030	men	_
21-42	4031-4032	.	_

22-1	4033-4035	We	_
22-2	4036-4040	used	_
22-3	4041-4045	this	_
22-4	4046-4048	as	_
22-5	4049-4050	a	_
22-6	4051-4058	measure	_
22-7	4059-4062	for	_
22-8	4063-4068	binge	_
22-9	4069-4077	drinking	_
22-10	4078-4079	.	_

23-1	4080-4085	Total	_
23-2	4086-4092	drinks	_
23-3	4093-4095	in	_
23-4	4096-4099	the	_
23-5	4100-4104	past	_
23-6	4105-4107	30	_
23-7	4108-4112	days	_
23-8	4113-4116	was	_
23-9	4117-4121	also	_
23-10	4122-4132	calculated	_
23-11	4133-4137	from	_
23-12	4138-4141	the	_
23-13	4142-4146	TLFB	_
23-14	4147-4148	.	_

24-1	4149-4153	Past	_
24-2	4154-4160	30-day	_
24-3	4161-4169	drinking	_
24-4	4170-4173	was	_
24-5	4174-4178	used	_
24-6	4179-4185	rather	_
24-7	4186-4190	than	_
24-8	4191-4197	90-day	_
24-9	4198-4206	drinking	_
24-10	4207-4212	given	_
24-11	4213-4217	that	_
24-12	4218-4220	we	_
24-13	4221-4225	were	_
24-14	4226-4236	interested	_
24-15	4237-4239	in	_
24-16	4240-4246	recent	_
24-17	4247-4255	drinking	_
24-18	4256-4257	,	_
24-19	4258-4261	and	_
24-20	4262-4266	that	_
24-21	4267-4273	recent	_
24-22	4274-4281	reports	_
24-23	4282-4284	of	_
24-24	4285-4293	drinking	_
24-25	4294-4297	may	_
24-26	4298-4300	be	_
24-27	4301-4305	more	_
24-28	4306-4314	reliable	_
24-29	4315-4316	.	_

25-1	4317-4328	Impulsivity	_
25-2	4329-4337	measures	_
25-3	4338-4347	Impulsive	_
25-4	4348-4358	behavioral	_
25-5	4359-4365	traits	_
25-6	4366-4370	were	_
25-7	4371-4379	measured	_
25-8	4380-4385	using	_
25-9	4386-4389	the	_
25-10	4390-4397	Barratt	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
25-11	4398-4411	Impulsiveness	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
25-12	4412-4417	Scale	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
25-13	4418-4419	(	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
25-14	4420-4426	BIS-11	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
25-15	4427-4428	)	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
25-16	4429-4432	and	_
25-17	4433-4436	the	_
25-18	4437-4443	UPPS-P	http://maven.renci.org/NeuroBridge/neurobridge#ImpulsiveSensationSeekingScale
25-19	4444-4453	Impulsive	http://maven.renci.org/NeuroBridge/neurobridge#ImpulsiveSensationSeekingScale
25-20	4454-4462	Behavior	http://maven.renci.org/NeuroBridge/neurobridge#ImpulsiveSensationSeekingScale
25-21	4463-4468	Scale	http://maven.renci.org/NeuroBridge/neurobridge#ImpulsiveSensationSeekingScale
25-22	4469-4470	,	_
25-23	4471-4474	two	_
25-24	4475-4477	of	_
25-25	4478-4481	the	_
25-26	4482-4486	most	_
25-27	4487-4498	widely-used	_
25-28	4499-4510	self-report	_
25-29	4511-4516	tools	_
25-30	4517-4519	in	_
25-31	4520-4523	the	_
25-32	4524-4534	evaluation	_
25-33	4535-4537	of	_
25-34	4538-4543	trait	_
25-35	4544-4555	impulsivity	_
25-36	4556-4557	.	_

26-1	4558-4561	The	_
26-2	4562-4568	BIS-11	_
26-3	4569-4574	scale	_
26-4	4575-4584	evaluates	_
26-5	4585-4594	impulsive	_
26-6	4595-4603	behavior	_
26-7	4604-4606	in	_
26-8	4607-4614	general	_
26-9	4615-4616	,	_
26-10	4617-4620	and	_
26-11	4621-4624	the	_
26-12	4625-4630	motor	_
26-13	4631-4632	,	_
26-14	4633-4644	attentional	_
26-15	4645-4648	and	_
26-16	4649-4661	non-planning	_
26-17	4662-4672	sub-scales	_
26-18	4673-4681	evaluate	_
26-19	4682-4688	acting	_
26-20	4689-4696	without	_
26-21	4697-4705	thinking	_
26-22	4706-4707	,	_
26-23	4708-4717	inability	_
26-24	4718-4720	to	_
26-25	4721-4726	focus	_
26-26	4727-4736	attention	_
26-27	4737-4740	and	_
26-28	4741-4745	lack	_
26-29	4746-4748	of	_
26-30	4749-4760	forethought	_
26-31	4761-4762	,	_
26-32	4763-4775	respectively	_
26-33	4776-4777	.	_

27-1	4778-4781	The	_
27-2	4782-4788	UPPS-P	_
27-3	4789-4797	measures	_
27-4	4798-4809	personality	_
27-5	4810-4816	traits	_
27-6	4817-4826	conducive	_
27-7	4827-4829	to	_
27-8	4830-4839	impulsive	_
27-9	4840-4848	behavior	_
27-10	4849-4858	including	_
27-11	4859-4866	Urgency	_
27-12	4867-4868	(	_
27-13	4869-4877	negative	_
27-14	4878-4879	)	_
27-15	4880-4889	—tendency	_
27-16	4890-4892	to	_
27-17	4893-4904	impulsively	_
27-18	4905-4908	act	_
27-19	4909-4914	under	_
27-20	4915-4921	strong	_
27-21	4922-4930	negative	_
27-22	4931-4939	emotions	_
27-23	4940-4941	,	_
27-24	4942-4955	Premeditation	_
27-25	4956-4957	(	_
27-26	4958-4962	lack	_
27-27	4963-4965	of	_
27-28	4966-4967	)	_
27-29	4968-4977	—tendency	_
27-30	4978-4980	to	_
27-31	4981-4984	act	_
27-32	4985-4992	without	_
27-33	4993-5001	thinking	_
27-34	5002-5003	,	_
27-35	5004-5016	Perseverance	_
27-36	5017-5018	(	_
27-37	5019-5023	lack	_
27-38	5024-5026	of	_
27-39	5027-5028	)	_
27-40	5029-5031	to	_
27-41	5032-5038	remain	_
27-42	5039-5046	focused	_
27-43	5047-5049	on	_
27-44	5050-5051	a	_
27-45	5052-5056	task	_
27-46	5057-5058	,	_
27-47	5059-5085	Sensation-seeking—tendency	_
27-48	5086-5088	to	_
27-49	5089-5093	seek	_
27-50	5094-5097	out	_
27-51	5098-5113	novel/thrilling	_
27-52	5114-5125	experiences	_
27-53	5126-5127	,	_
27-54	5128-5131	and	_
27-55	5132-5157	Positive-urgency—tendency	_
27-56	5158-5160	to	_
27-57	5161-5172	impulsively	_
27-58	5173-5176	act	_
27-59	5177-5182	under	_
27-60	5183-5189	strong	_
27-61	5190-5198	positive	_
27-62	5199-5207	emotions	_
27-63	5208-5209	.	_

28-1	5210-5212	We	_
28-2	5213-5217	also	_
28-3	5218-5227	evaluated	_
28-4	5228-5234	choice	_
28-5	5235-5246	impulsivity	_
28-6	5247-5251	with	_
28-7	5252-5255	the	_
28-8	5256-5261	Delay	_
28-9	5262-5273	Discounting	http://maven.renci.org/NeuroBridge/neurobridge#FingerTappingTask
28-10	5274-5278	Task	http://maven.renci.org/NeuroBridge/neurobridge#FingerTappingTask
28-11	5279-5280	(	http://maven.renci.org/NeuroBridge/neurobridge#FingerTappingTask
28-12	5281-5284	DDT	http://maven.renci.org/NeuroBridge/neurobridge#FingerTappingTask
28-13	5285-5286	)	http://maven.renci.org/NeuroBridge/neurobridge#FingerTappingTask
28-14	5287-5288	.	_

29-1	5289-5292	The	_
29-2	5293-5296	DDT	_
29-3	5297-5305	measures	_
29-4	5306-5317	impulsivity	_
29-5	5318-5320	by	_
29-6	5321-5331	presenting	_
29-7	5332-5335	the	_
29-8	5336-5343	subject	_
29-9	5344-5348	with	_
29-10	5349-5350	a	_
29-11	5351-5357	series	_
29-12	5358-5360	of	_
29-13	5361-5373	hypothetical	_
29-14	5374-5381	choices	_
29-15	5382-5389	between	_
29-16	5390-5399	receiving	_
29-17	5400-5401	a	_
29-18	5402-5409	smaller	_
29-19	5410-5419	immediate	_
29-20	5420-5428	monetary	_
29-21	5429-5435	reward	_
29-22	5436-5438	or	_
29-23	5439-5440	a	_
29-24	5441-5447	larger	_
29-25	5448-5455	delayed	_
29-26	5456-5462	reward	_
29-27	5463-5464	.	_

30-1	5465-5473	Subjects	_
30-2	5474-5478	were	_
30-3	5479-5488	presented	_
30-4	5489-5491	as	_
30-5	5492-5497	their	_
30-6	5498-5507	immediate	_
30-7	5508-5514	reward	_
30-8	5515-5521	values	_
30-9	5522-5529	between	_
30-10	5530-5531	$	_
30-11	5532-5535	100	_
30-12	5536-5539	and	_
30-13	5540-5541	$	_
30-14	5542-5543	0	_
30-15	5544-5551	dollars	_
30-16	5552-5554	in	_
30-17	5555-5565	increments	_
30-18	5566-5568	of	_
30-19	5569-5570	$	_
30-20	5571-5573	10	_
30-21	5574-5575	,	_
30-22	5576-5581	while	_
30-23	5582-5585	the	_
30-24	5586-5593	delayed	_
30-25	5594-5600	reward	_
30-26	5601-5604	was	_
30-27	5605-5606	$	_
30-28	5607-5610	100	_
30-29	5611-5612	.	_

31-1	5613-5619	Delays	_
31-2	5620-5624	were	_
31-3	5625-5626	0	_
31-4	5627-5628	,	_
31-5	5629-5630	7	_
31-6	5631-5632	,	_
31-7	5633-5635	14	_
31-8	5636-5637	,	_
31-9	5638-5640	20	_
31-10	5641-5642	,	_
31-11	5643-5645	25	_
31-12	5646-5647	,	_
31-13	5648-5650	or	_
31-14	5651-5653	30	_
31-15	5654-5658	days	_
31-16	5659-5660	.	_

32-1	5661-5669	Subjects	_
32-2	5670-5679	completed	_
32-3	5680-5686	trials	_
32-4	5687-5691	with	_
32-5	5692-5695	all	_
32-6	5696-5706	iterations	_
32-7	5707-5709	of	_
32-8	5710-5715	these	_
32-9	5716-5726	parameters	_
32-10	5727-5728	.	_

33-1	5729-5732	The	_
33-2	5733-5737	rate	_
33-3	5738-5740	of	_
33-4	5741-5752	discounting	_
33-5	5753-5755	of	_
33-6	5756-5759	the	_
33-7	5760-5767	delayed	_
33-8	5768-5775	outcome	_
33-9	5776-5777	(	_
33-10	5778-5779	k	_
33-11	5780-5781	)	_
33-12	5782-5785	was	_
33-13	5786-5796	calculated	_
33-14	5797-5800	and	_
33-15	5801-5805	then	_
33-16	5806-5807	a	_
33-17	5808-5815	natural	_
33-18	5816-5834	log-transformation	_
33-19	5835-5838	was	_
33-20	5839-5846	applied	_
33-21	5847-5849	to	_
33-22	5850-5857	correct	_
33-23	5858-5861	for	_
33-24	5862-5865	the	_
33-25	5866-5876	non-normal	_
33-26	5877-5889	distribution	_
33-27	5890-5892	of	_
33-28	5893-5894	k	_
33-29	5895-5901	values	_
33-30	5902-5903	.	_

34-1	5904-5907	The	_
34-2	5908-5917	resulting	_
34-3	5918-5920	ln	_
34-4	5921-5922	(	_
34-5	5923-5924	k	_
34-6	5925-5926	)	_
34-7	5927-5929	is	_
34-8	5930-5934	used	_
34-9	5935-5937	to	_
34-10	5938-5947	represent	_
34-11	5948-5953	delay	_
34-12	5954-5965	discounting	_
34-13	5966-5967	,	_
34-14	5968-5973	where	_
34-15	5974-5980	higher	_
34-16	5981-5983	ln	_
34-17	5984-5985	(	_
34-18	5986-5987	k	_
34-19	5988-5989	)	_
34-20	5990-5996	values	_
34-21	5997-6001	mean	_
34-22	6002-6009	greater	_
34-23	6010-6020	preference	_
34-24	6021-6024	for	_
34-25	6025-6034	immediate	_
34-26	6035-6042	rewards	_
34-27	6043-6044	(	_
34-28	6045-6048	see	_
34-29	6049-6054	Table	_
34-30	6055-6056	1	_
34-31	6057-6060	for	_
34-32	6061-6072	descriptive	_
34-33	6073-6083	statistics	_
34-34	6084-6086	of	_
34-35	6087-6095	drinking	_
34-36	6096-6099	and	_
34-37	6100-6111	impulsivity	_
34-38	6112-6118	scores	_
34-39	6119-6122	for	_
34-40	6123-6126	the	_
34-41	6127-6133	sample	_
34-42	6134-6135	)	_
34-43	6136-6137	.	_

35-1	6138-6150	Experimental	_
35-2	6151-6157	design	_
35-3	6158-6161	and	_
35-4	6162-6173	statistical	_
35-5	6174-6182	analysis	_
35-6	6183-6190	Overall	_
35-7	6191-6199	timeline	_
35-8	6200-6202	In	_
35-9	6203-6207	this	_
35-10	6208-6219	two-session	_
35-11	6220-6225	study	_
35-12	6226-6227	,	_
35-13	6228-6235	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
35-14	6236-6241	light	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
35-15	6242-6250	drinkers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
35-16	6251-6259	received	_
35-17	6260-6262	an	_
35-18	6263-6265	IV	_
35-19	6266-6273	alcohol	_
35-20	6274-6282	infusion	_
35-21	6283-6285	on	_
35-22	6286-6289	two	_
35-23	6290-6298	separate	_
35-24	6299-6303	days	_
35-25	6304-6305	.	_

36-1	6306-6309	The	_
36-2	6310-6315	first	_
36-3	6316-6323	session	_
36-4	6324-6327	was	_
36-5	6328-6337	conducted	_
36-6	6338-6345	outside	_
36-7	6346-6349	the	_
36-8	6350-6357	scanner	_
36-9	6358-6360	to	_
36-10	6361-6370	establish	_
36-11	6371-6374	the	_
36-12	6375-6382	alcohol	_
36-13	6383-6391	infusion	_
36-14	6392-6396	rate	_
36-15	6397-6404	profile	_
36-16	6405-6407	to	_
36-17	6408-6415	achieve	_
36-18	6416-6419	and	_
36-19	6420-6428	maintain	_
36-20	6429-6432	the	_
36-21	6433-6439	target	_
36-22	6440-6444	BrAC	_
36-23	6445-6453	exposure	_
36-24	6454-6455	,	_
36-25	6456-6459	and	_
36-26	6460-6462	to	_
36-27	6463-6469	ensure	_
36-28	6470-6482	tolerability	_
36-29	6483-6484	.	_

37-1	6485-6488	The	_
37-2	6489-6496	alcohol	_
37-3	6497-6505	infusion	_
37-4	6506-6509	for	_
37-5	6510-6513	the	_
37-6	6514-6520	second	_
37-7	6521-6528	session	_
37-8	6529-6532	was	_
37-9	6533-6542	conducted	_
37-10	6543-6549	inside	_
37-11	6550-6553	the	_
37-12	6554-6561	scanner	_
37-13	6562-6564	at	_
37-14	6565-6570	least	_
37-15	6571-6576	three	_
37-16	6577-6581	days	_
37-17	6582-6587	after	_
37-18	6588-6591	the	_
37-19	6592-6597	first	_
37-20	6598-6605	session	_
37-21	6606-6607	(	_
37-22	6608-6611	Fig	_
37-23	6612-6613	1	_
37-24	6614-6615	)	_
37-25	6616-6617	.	_

38-1	6618-6630	Participants	_
38-2	6631-6635	were	_
38-3	6636-6641	asked	_
38-4	6642-6644	to	_
38-5	6645-6649	fast	_
38-6	6650-6653	the	_
38-7	6654-6659	night	_
38-8	6660-6666	before	_
38-9	6667-6671	each	_
38-10	6672-6679	session	_
38-11	6680-6681	.	_

39-1	6682-6684	At	_
39-2	6685-6688	the	_
39-3	6689-6694	start	_
39-4	6695-6697	of	_
39-5	6698-6702	each	_
39-6	6703-6708	visit	_
39-7	6709-6710	,	_
39-8	6711-6717	breath	_
39-9	6718-6725	alcohol	_
39-10	6726-6732	levels	_
39-11	6733-6734	,	_
39-12	6735-6740	urine	_
39-13	6741-6750	pregnancy	_
39-14	6751-6756	tests	_
39-15	6757-6758	(	_
39-16	6759-6761	if	_
39-17	6762-6772	applicable	_
39-18	6773-6774	)	_
39-19	6775-6778	and	_
39-20	6779-6784	urine	_
39-21	6785-6789	drug	_
39-22	6790-6797	screens	_
39-23	6798-6802	were	_
39-24	6803-6812	collected	_
39-25	6813-6814	.	_

40-1	6815-6817	In	_
40-2	6818-6826	addition	_
40-3	6827-6828	,	_
40-4	6829-6831	we	_
40-5	6832-6841	conducted	_
40-6	6842-6843	a	_
40-7	6844-6849	brief	_
40-8	6850-6857	history	_
40-9	6858-6867	interview	_
40-10	6868-6873	about	_
40-11	6874-6880	recent	_
40-12	6881-6888	alcohol	_
40-13	6889-6890	,	_
40-14	6891-6901	medication	_
40-15	6902-6903	,	_
40-16	6904-6907	and	_
40-17	6908-6916	nicotine	_
40-18	6917-6920	use	_
40-19	6921-6922	,	_
40-20	6923-6930	changes	_
40-21	6931-6933	in	_
40-22	6934-6942	physical	_
40-23	6943-6949	health	_
40-24	6950-6951	,	_
40-25	6952-6955	and	_
40-26	6956-6968	menstruation	_
40-27	6969-6970	(	_
40-28	6971-6973	if	_
40-29	6974-6984	applicable	_
40-30	6985-6986	)	_
40-31	6987-6988	.	_

41-1	6989-6996	Alcohol	_
41-2	6997-7005	infusion	_
41-3	7006-7008	to	_
41-4	7009-7014	binge	_
41-5	7015-7020	level	_
41-6	7021-7029	exposure	_
41-7	7030-7032	We	_
41-8	7033-7042	performed	_
41-9	7043-7046	the	_
41-10	7047-7054	alcohol	_
41-11	7055-7063	infusion	_
41-12	7064-7073	procedure	_
41-13	7074-7083	following	_
41-14	7084-7094	previously	_
41-15	7095-7104	published	_
41-16	7105-7112	methods	_
41-17	7113-7114	(	_
41-18	7115-7119	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
41-19	7120-7123	and	_
41-20	7124-7127	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
41-21	7128-7129	)	_
41-22	7130-7131	.	_

42-1	7132-7134	In	_
42-2	7135-7139	both	_
42-3	7140-7148	sessions	_
42-4	7149-7150	,	_
42-5	7151-7163	participants	_
42-6	7164-7172	received	_
42-7	7173-7175	an	_
42-8	7176-7187	intravenous	_
42-9	7188-7189	(	_
42-10	7190-7192	IV	_
42-11	7193-7194	)	_
42-12	7195-7203	infusion	_
42-13	7204-7206	of	_
42-14	7207-7208	6	_
42-15	7209-7210	%	_
42-16	7211-7214	v/v	_
42-17	7215-7222	ethanol	_
42-18	7223-7231	solution	_
42-19	7232-7234	in	_
42-20	7235-7241	saline	_
42-21	7242-7244	to	_
42-22	7245-7252	achieve	_
42-23	7253-7254	a	_
42-24	7255-7261	target	_
42-25	7262-7268	breath	_
42-26	7269-7276	alcohol	_
42-27	7277-7290	concentration	_
42-28	7291-7292	(	_
42-29	7293-7297	BrAC	_
42-30	7298-7299	)	_
42-31	7300-7302	of	_
42-32	7303-7307	0.08	_
42-33	7308-7309	±	_
42-34	7310-7315	0.005	_
42-35	7316-7320	g/dl	_
42-36	7321-7323	at	_
42-37	7324-7326	15	_
42-38	7327-7330	min	_
42-39	7331-7336	after	_
42-40	7337-7340	the	_
42-41	7341-7346	start	_
42-42	7347-7349	of	_
42-43	7350-7353	the	_
42-44	7354-7362	infusion	_
42-45	7363-7364	,	_
42-46	7365-7368	and	_
42-47	7369-7371	to	_
42-48	7372-7380	maintain	_
42-49	7381-7382	(	_
42-50	7383-7385	or	_
42-51	7386-7391	clamp	_
42-52	7392-7393	)	_
42-53	7394-7397	the	_
42-54	7398-7404	target	_
42-55	7405-7409	BrAC	_
42-56	7410-7415	level	_
42-57	7416-7419	for	_
42-58	7420-7422	30	_
42-59	7423-7426	min	_
42-60	7427-7428	(	_
42-61	7429-7432	Fig	_
42-62	7433-7434	1	_
42-63	7435-7436	)	_
42-64	7437-7438	.	_

43-1	7439-7442	The	_
43-2	7443-7456	infusion-rate	_
43-3	7457-7464	profile	_
43-4	7465-7468	was	_
43-5	7469-7477	computed	_
43-6	7478-7481	for	_
43-7	7482-7486	each	_
43-8	7487-7494	subject	_
43-9	7495-7500	using	_
43-10	7501-7502	a	_
43-11	7503-7524	physiologically-based	_
43-12	7525-7540	pharmacokinetic	_
43-13	7541-7542	(	_
43-14	7543-7547	PBPK	_
43-15	7548-7549	)	_
43-16	7550-7561	model-based	_
43-17	7562-7571	algorithm	_
43-18	7572-7573	,	_
43-19	7574-7578	with	_
43-20	7579-7593	individualized	_
43-21	7594-7603	estimates	_
43-22	7604-7606	of	_
43-23	7607-7610	the	_
43-24	7611-7616	model	_
43-25	7617-7627	parameters	_
43-26	7628-7637	estimated	_
43-27	7638-7642	from	_
43-28	7643-7646	the	_
43-29	7647-7654	subject	_
43-30	7655-7656	’	_
43-31	7657-7658	s	_
43-32	7659-7665	height	_
43-33	7666-7667	,	_
43-34	7668-7674	weight	_
43-35	7675-7676	,	_
43-36	7677-7680	age	_
43-37	7681-7684	and	_
43-38	7685-7688	sex	_
43-39	7689-7690	.	_

44-1	7691-7697	During	_
44-2	7698-7701	the	_
44-3	7702-7707	first	_
44-4	7708-7715	session	_
44-5	7716-7725	conducted	_
44-6	7726-7733	outside	_
44-7	7734-7737	the	_
44-8	7738-7745	scanner	_
44-9	7746-7747	,	_
44-10	7748-7754	serial	_
44-11	7755-7760	BrACs	_
44-12	7761-7765	were	_
44-13	7766-7774	measured	_
44-14	7775-7777	at	_
44-15	7778-7786	frequent	_
44-16	7787-7796	intervals	_
44-17	7797-7798	(	_
44-18	7799-7803	5–15	_
44-19	7804-7811	minutes	_
44-20	7812-7813	)	_
44-21	7814-7819	using	_
44-22	7820-7823	the	_
44-23	7824-7832	Alcotest	_
44-24	7833-7838	7410+	_
44-25	7839-7847	handheld	_
44-26	7848-7860	breathalyzer	_
44-27	7861-7862	(	_
44-28	7863-7869	Drager	_
44-29	7870-7876	Safety	_
44-30	7877-7881	Inc.	_
44-31	7882-7883	,	_
44-32	7884-7886	CO	_
44-33	7887-7888	)	_
44-34	7889-7890	,	_
44-35	7891-7893	to	_
44-36	7894-7900	ensure	_
44-37	7901-7905	that	_
44-38	7906-7910	each	_
44-39	7911-7915	BrAC	_
44-40	7916-7919	was	_
44-41	7920-7926	within	_
44-42	7927-7932	0.005	_
44-43	7933-7937	g/dl	_
44-44	7938-7940	of	_
44-45	7941-7944	the	_
44-46	7945-7951	target	_
44-47	7952-7953	,	_
44-48	7954-7957	and	_
44-49	7958-7960	to	_
44-50	7961-7967	enable	_
44-51	7968-7973	minor	_
44-52	7974-7985	adjustments	_
44-53	7986-7988	to	_
44-54	7989-7992	the	_
44-55	7993-8001	infusion	_
44-56	8002-8007	rates	_
44-57	8008-8010	to	_
44-58	8011-8019	overcome	_
44-59	8020-8026	errors	_
44-60	8027-8029	in	_
44-61	8030-8039	parameter	_
44-62	8040-8050	estimation	_
44-63	8051-8054	and	_
44-64	8055-8067	experimental	_
44-65	8068-8079	variability	_
44-66	8080-8081	.	_

45-1	8082-8085	The	_
45-2	8086-8094	adjusted	_
45-3	8095-8103	infusion	_
45-4	8104-8108	rate	_
45-5	8109-8116	profile	_
45-6	8117-8121	from	_
45-7	8122-8125	the	_
45-8	8126-8131	first	_
45-9	8132-8139	session	_
45-10	8140-8143	was	_
45-11	8144-8148	used	_
45-12	8149-8151	in	_
45-13	8152-8155	the	_
45-14	8156-8163	imaging	_
45-15	8164-8171	session	_
45-16	8172-8174	to	_
45-17	8175-8184	replicate	_
45-18	8185-8188	the	_
45-19	8189-8195	target	_
45-20	8196-8200	BrAC	_
45-21	8201-8208	profile	_
45-22	8209-8212	for	_
45-23	8213-8217	each	_
45-24	8218-8225	subject	_
45-25	8226-8227	.	_

46-1	8228-8232	This	_
46-2	8233-8241	approach	_
46-3	8242-8245	has	_
46-4	8246-8250	been	_
46-5	8251-8255	used	_
46-6	8256-8258	to	_
46-7	8259-8271	successfully	_
46-8	8272-8279	achieve	_
46-9	8280-8283	and	_
46-10	8284-8292	maintain	_
46-11	8293-8299	target	_
46-12	8300-8305	BrACs	_
46-13	8306-8307	,	_
46-14	8308-8310	as	_
46-15	8311-8319	verified	_
46-16	8320-8322	by	_
46-17	8323-8328	blood	_
46-18	8329-8336	alcohol	_
46-19	8337-8351	concentrations	_
46-20	8352-8360	measured	_
46-21	8361-8363	in	_
46-22	8364-8371	samples	_
46-23	8372-8377	drawn	_
46-24	8378-8384	during	_
46-25	8385-8388	the	_
46-26	8389-8393	scan	_
46-27	8394-8396	in	_
46-28	8397-8402	other	_
46-29	8403-8415	neuroimaging	_
46-30	8416-8423	studies	_
46-31	8424-8425	.	_

47-1	8426-8431	After	_
47-2	8432-8435	the	_
47-3	8436-8439	end	_
47-4	8440-8442	of	_
47-5	8443-8446	the	_
47-6	8447-8455	infusion	_
47-7	8456-8457	,	_
47-8	8458-8466	subjects	_
47-9	8467-8471	were	_
47-10	8472-8480	provided	_
47-11	8481-8482	a	_
47-12	8483-8487	meal	_
47-13	8488-8489	,	_
47-14	8490-8493	and	_
47-15	8494-8498	BrAC	_
47-16	8499-8502	was	_
47-17	8503-8510	tracked	_
47-18	8511-8516	until	_
47-19	8517-8519	it	_
47-20	8520-8527	dropped	_
47-21	8528-8530	to	_
47-22	8531-8535	0.02	_
47-23	8536-8540	g/dL	_
47-24	8541-8543	or	_
47-25	8544-8549	below	_
47-26	8550-8551	,	_
47-27	8552-8554	at	_
47-28	8555-8560	which	_
47-29	8561-8565	time	_
47-30	8566-8574	subjects	_
47-31	8575-8579	were	_
47-32	8580-8585	taken	_
47-33	8586-8590	home	_
47-34	8591-8593	by	_
47-35	8594-8595	a	_
47-36	8596-8606	designated	_
47-37	8607-8613	driver	_
47-38	8614-8616	or	_
47-39	8617-8621	taxi	_
47-40	8622-8623	.	_

48-1	8624-8636	Neuroimaging	_
48-2	8637-8648	acquisition	_
48-3	8649-8652	and	_
48-4	8653-8666	preprocessing	_
48-5	8667-8673	During	_
48-6	8674-8681	session	_
48-7	8682-8683	2	_
48-8	8684-8685	,	_
48-9	8686-8691	after	_
48-10	8692-8695	the	_
48-11	8696-8698	IV	_
48-12	8699-8708	catheters	_
48-13	8709-8713	were	_
48-14	8714-8720	placed	_
48-15	8721-8724	for	_
48-16	8725-8732	alcohol	_
48-17	8733-8741	infusion	_
48-18	8742-8743	,	_
48-19	8744-8756	participants	_
48-20	8757-8761	were	_
48-21	8762-8768	placed	_
48-22	8769-8771	in	_
48-23	8772-8773	a	_
48-24	8774-8776	3T	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
48-25	8777-8784	SIEMENS	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
48-26	8785-8790	Skyra	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
48-27	8791-8793	MR	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
48-28	8794-8801	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
48-29	8802-8804	at	_
48-30	8805-8808	the	_
48-31	8809-8812	NMR	_
48-32	8813-8821	Research	_
48-33	8822-8828	Center	_
48-34	8829-8831	at	_
48-35	8832-8835	the	_
48-36	8836-8839	NIH	_
48-37	8840-8841	.	_

49-1	8842-8848	Before	_
49-2	8849-8857	starting	_
49-3	8858-8861	the	_
49-4	8862-8864	IV	_
49-5	8865-8873	infusion	_
49-6	8874-8876	of	_
49-7	8877-8884	alcohol	_
49-8	8885-8886	,	_
49-9	8887-8888	a	_
49-10	8889-8894	5-min	_
49-11	8895-8901	closed	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
49-12	8902-8906	eyes	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
49-13	8907-8920	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
49-14	8921-8925	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
49-15	8926-8930	scan	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
49-16	8931-8934	was	_
49-17	8935-8943	acquired	_
49-18	8944-8948	with	_
49-19	8949-8951	an	_
49-20	8952-8963	echo-planar	_
49-21	8964-8971	imaging	_
49-22	8972-8980	sequence	_
49-23	8981-8982	(	_
49-24	8983-8985	36	_
49-25	8986-8991	axial	_
49-26	8992-8998	slices	_
49-27	8999-9000	,	_
49-28	9001-9004	3.8	_
49-29	9005-9007	mm	_
49-30	9008-9017	thickness	_
49-31	9018-9019	,	_
49-32	9020-9022	64	_
49-33	9023-9024	×	_
49-34	9025-9027	64	_
49-35	9028-9034	matrix	_
49-36	9035-9038	and	_
49-37	9039-9049	repetition	_
49-38	9050-9054	time	_
49-39	9055-9057	of	_
49-40	9058-9062	2000	_
49-41	9063-9065	ms	_
49-42	9066-9067	,	_
49-43	9068-9072	echo	_
49-44	9073-9077	time	_
49-45	9078-9080	30	_
49-46	9081-9082	,	_
49-47	9083-9087	flip	_
49-48	9088-9093	angle	_
49-49	9094-9096	90	_
49-50	9097-9098	)	_
49-51	9099-9100	.	_

50-1	9101-9106	After	_
50-2	9107-9117	collecting	_
50-3	9118-9122	this	_
50-4	9123-9131	baseline	_
50-5	9132-9145	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
50-6	9146-9150	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
50-7	9151-9155	scan	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
50-8	9156-9157	,	_
50-9	9158-9161	the	_
50-10	9162-9169	alcohol	_
50-11	9170-9178	infusion	_
50-12	9179-9186	started	_
50-13	9187-9190	and	_
50-14	9191-9195	once	_
50-15	9196-9199	the	_
50-16	9200-9206	target	_
50-17	9207-9210	BAC	_
50-18	9211-9214	was	_
50-19	9215-9223	achieved	_
50-20	9224-9225	,	_
50-21	9226-9227	a	_
50-22	9228-9237	10-minute	_
50-23	9238-9245	waiting	_
50-24	9246-9252	period	_
50-25	9253-9256	was	_
50-26	9257-9264	allowed	_
50-27	9265-9267	to	_
50-28	9268-9274	ensure	_
50-29	9275-9278	the	_
50-30	9279-9282	BAC	_
50-31	9283-9286	was	_
50-32	9287-9293	stable	_
50-33	9294-9296	at	_
50-34	9297-9300	the	_
50-35	9301-9305	0.08	_
50-36	9306-9310	g/dl	_
50-37	9311-9316	level	_
50-38	9317-9318	.	_

51-1	9319-9325	During	_
51-2	9326-9329	the	_
51-3	9330-9337	waiting	_
51-4	9338-9344	period	_
51-5	9345-9346	,	_
51-6	9347-9358	whole-brain	_
51-7	9359-9369	structural	_
51-8	9370-9373	and	_
51-9	9374-9392	diffusion-weighted	_
51-10	9393-9399	images	_
51-11	9400-9402	of	_
51-12	9403-9406	the	_
51-13	9407-9412	brain	_
51-14	9413-9417	were	_
51-15	9418-9427	collected	_
51-16	9428-9429	.	_

52-1	9430-9434	Then	_
52-2	9435-9436	,	_
52-3	9437-9438	a	_
52-4	9439-9445	second	_
52-5	9446-9457	eyes-closed	_
52-6	9458-9471	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
52-7	9472-9476	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
52-8	9477-9481	scan	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
52-9	9482-9485	was	_
52-10	9486-9495	collected	_
52-11	9496-9501	while	_
52-12	9502-9505	the	_
52-13	9506-9512	target	_
52-14	9513-9516	BAC	_
52-15	9517-9518	(	_
52-16	9519-9523	0.08	_
52-17	9524-9528	g/dl	_
52-18	9529-9530	)	_
52-19	9531-9534	was	_
52-20	9535-9545	maintained	_
52-21	9546-9547	.	_

53-1	9548-9557	Following	_
53-2	9558-9561	the	_
53-3	9562-9565	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
53-4	9566-9573	session	_
53-5	9574-9575	,	_
53-6	9576-9579	the	_
53-7	9580-9584	Drug	_
53-8	9585-9592	Effects	_
53-9	9593-9606	Questionnaire	http://maven.renci.org/NeuroBridge/neurobridge#Questionnaire
53-10	9607-9610	was	_
53-11	9611-9615	used	_
53-12	9616-9618	to	_
53-13	9619-9627	evaluate	_
53-14	9628-9631	and	_
53-15	9632-9640	quantify	_
53-16	9641-9651	subjective	_
53-17	9652-9659	effects	_
53-18	9660-9662	of	_
53-19	9663-9670	alcohol	_
53-20	9671-9672	(	_
53-21	9673-9676	DEQ	_
53-22	9677-9678	)	_
53-23	9679-9680	.	_

54-1	9681-9685	CONN	_
54-2	9686-9693	ver.17f	_
54-3	9694-9695	(	_
54-4	9696-9700	http	_
54-5	9701-9702	:	_
54-6	9703-9725	//www.conn-toolbox.org	_
54-7	9726-9727	)	_
54-8	9728-9729	,	_
54-9	9730-9731	a	_
54-10	9732-9748	MATLAB/SPM-based	_
54-11	9749-9750	(	_
54-12	9751-9777	www.fil.ion.ucl.ac.uk/spm/	_
54-13	9778-9779	)	_
54-14	9780-9788	software	_
54-15	9789-9790	,	_
54-16	9791-9794	was	_
54-17	9795-9799	used	_
54-18	9800-9802	to	_
54-19	9803-9810	conduct	_
54-20	9811-9827	spatial/temporal	_
54-21	9828-9841	preprocessing	_
54-22	9842-9845	and	_
54-23	9846-9854	analyses	_
54-24	9855-9856	.	_

55-1	9857-9864	Spatial	_
55-2	9865-9878	preprocessing	_
55-3	9879-9887	included	_
55-4	9888-9900	slice-timing	_
55-5	9901-9911	correction	_
55-6	9912-9913	,	_
55-7	9914-9925	realignment	_
55-8	9926-9927	,	_
55-9	9928-9943	co-registration	_
55-10	9944-9945	,	_
55-11	9946-9959	normalization	_
55-12	9960-9961	,	_
55-13	9962-9965	and	_
55-14	9966-9973	spatial	_
55-15	9974-9983	smoothing	_
55-16	9984-9985	(	_
55-17	9986-9987	8	_
55-18	9988-9990	mm	_
55-19	9991-9992	)	_
55-20	9993-9994	.	_

56-1	9995-10000	Using	_
56-2	10001-10004	the	_
56-3	10005-10012	default	_
56-4	10013-10021	settings	_
56-5	10022-10024	in	_
56-6	10025-10029	CONN	_
56-7	10030-10031	,	_
56-8	10032-10038	images	_
56-9	10039-10043	were	_
56-10	10044-10052	resliced	_
56-11	10053-10057	into	_
56-12	10058-10067	isotropic	_
56-13	10068-10071	2mm	_
56-14	10072-10078	voxels	_
56-15	10079-10080	.	_

57-1	10081-10091	Anatomical	_
57-2	10092-10099	volumes	_
57-3	10100-10104	were	_
57-4	10105-10114	segmented	_
57-5	10115-10119	into	_
57-6	10120-10124	grey	_
57-7	10125-10131	matter	_
57-8	10132-10133	,	_
57-9	10134-10139	white	_
57-10	10140-10146	matter	_
57-11	10147-10148	,	_
57-12	10149-10152	and	_
57-13	10153-10166	cerebrospinal	_
57-14	10167-10172	fluid	_
57-15	10173-10174	(	_
57-16	10175-10178	CSF	_
57-17	10179-10180	)	_
57-18	10181-10186	areas	_
57-19	10187-10190	and	_
57-20	10191-10194	the	_
57-21	10195-10204	resulting	_
57-22	10205-10210	masks	_
57-23	10211-10215	were	_
57-24	10216-10222	eroded	_
57-25	10223-10225	to	_
57-26	10226-10234	minimize	_
57-27	10235-10242	partial	_
57-28	10243-10249	volume	_
57-29	10250-10257	effects	_
57-30	10258-10259	.	_

58-1	10260-10262	At	_
58-2	10263-10266	the	_
58-3	10267-10277	individual	_
58-4	10278-10283	level	_
58-5	10284-10285	,	_
58-6	10286-10289	the	_
58-7	10290-10298	temporal	_
58-8	10299-10309	timeseries	_
58-9	10310-10312	of	_
58-10	10313-10316	the	_
58-11	10317-10337	participant-specific	_
58-12	10338-10341	six	_
58-13	10342-10362	rotation-translation	_
58-14	10363-10369	motion	_
58-15	10370-10380	parameters	_
58-16	10381-10384	and	_
58-17	10385-10388	the	_
58-18	10389-10399	timeseries	_
58-19	10400-10404	from	_
58-20	10405-10411	within	_
58-21	10412-10415	the	_
58-22	10416-10421	white	_
58-23	10422-10432	matter/CSF	_
58-24	10433-10438	masks	_
58-25	10439-10443	were	_
58-26	10444-10448	used	_
58-27	10449-10451	as	_
58-28	10452-10460	temporal	_
58-29	10461-10471	covariates	_
58-30	10472-10473	,	_
58-31	10474-10477	and	_
58-32	10478-10485	removed	_
58-33	10486-10490	from	_
58-34	10491-10494	the	_
58-35	10495-10500	blood	_
58-36	10501-10507	oxygen	_
58-37	10508-10523	level-dependent	_
58-38	10524-10525	(	_
58-39	10526-10530	BOLD	_
58-40	10531-10532	)	_
58-41	10533-10543	functional	_
58-42	10544-10548	data	_
58-43	10549-10554	using	_
58-44	10555-10561	linear	_
58-45	10562-10572	regression	_
58-46	10573-10574	.	_

59-1	10575-10578	The	_
59-2	10579-10588	resulting	_
59-3	10589-10597	residual	_
59-4	10598-10602	BOLD	_
59-5	10603-10613	timeseries	_
59-6	10614-10618	were	_
59-7	10619-10628	band-pass	_
59-8	10629-10637	filtered	_
59-9	10638-10639	(	_
59-10	10640-10647	0.008Hz	_
59-11	10648-10649	<	_
59-12	10650-10651	f	_
59-13	10652-10653	<	_
59-14	10654-10660	0.15Hz	_
59-15	10661-10662	)	_
59-16	10663-10664	.	_

60-1	10665-10677	Neuroimaging	_
60-2	10678-10686	analysis	_
60-3	10687-10689	To	_
60-4	10690-10693	our	_
60-5	10694-10703	knowledge	_
60-6	10704-10709	there	_
60-7	10710-10712	is	_
60-8	10713-10715	no	_
60-9	10716-10724	reported	_
60-10	10725-10737	sub-division	_
60-11	10738-10740	of	_
60-12	10741-10746	human	_
60-13	10747-10750	GPe	_
60-14	10751-10755	with	_
60-15	10756-10764	concrete	_
60-16	10765-10773	landmark	_
60-17	10774-10784	definition	_
60-18	10785-10791	and/or	_
60-19	10792-10801	Talairach	_
60-20	10802-10812	coordinate	_
60-21	10813-10824	demarcation	_
60-22	10825-10826	.	_

61-1	10827-10836	Therefore	_
61-2	10837-10838	,	_
61-3	10839-10842	for	_
61-4	10843-10848	these	_
61-5	10849-10857	analyses	_
61-6	10858-10859	,	_
61-7	10860-10862	we	_
61-8	10863-10867	used	_
61-9	10868-10873	right	_
61-10	10874-10877	and	_
61-11	10878-10882	left	_
61-12	10883-10886	GPe	_
61-13	10887-10892	masks	_
61-14	10893-10901	obtained	_
61-15	10902-10906	from	_
61-16	10907-10910	the	_
61-17	10911-10919	Lead-DBS	_
61-18	10920-10927	toolbox	_
61-19	10928-10929	(	_
61-20	10930-10934	http	_
61-21	10935-10936	:	_
61-22	10937-10956	//www.lead-dbs.org/	_
61-23	10957-10958	)	_
61-24	10959-10960	.	_

62-1	10961-10966	These	_
62-2	10967-10977	anatomical	_
62-3	10978-10983	masks	_
62-4	10984-10988	were	_
62-5	10989-10998	generated	_
62-6	10999-11004	using	_
62-7	11005-11011	manual	_
62-8	11012-11019	tracing	_
62-9	11020-11022	of	_
62-10	11023-11030	several	_
62-11	11031-11041	structural	_
62-12	11042-11046	MRIs	_
62-13	11047-11050	and	_
62-14	11051-11061	subsequent	_
62-15	11062-11077	co-registration	_
62-16	11078-11082	with	_
62-17	11083-11095	histological	_
62-18	11096-11103	studies	_
62-19	11104-11105	,	_
62-20	11106-11109	and	_
62-21	11110-11114	have	_
62-22	11115-11116	a	_
62-23	11117-11125	combined	_
62-24	11126-11132	volume	_
62-25	11133-11135	of	_
62-26	11136-11149	approximately	_
62-27	11150-11153	929	_
62-28	11154-11157	mm3	_
62-29	11158-11159	.	_

63-1	11160-11170	Seed-based	_
63-2	11171-11183	correlations	_
63-3	11184-11188	were	_
63-4	11189-11199	calculated	_
63-5	11200-11202	as	_
63-6	11203-11221	Fisher-transformed	_
63-7	11222-11231	bivariate	_
63-8	11232-11243	correlation	_
63-9	11244-11256	coefficients	_
63-10	11257-11264	between	_
63-11	11265-11268	the	_
63-12	11269-11273	BOLD	_
63-13	11274-11282	activity	_
63-14	11283-11293	timeseries	_
63-15	11294-11296	in	_
63-16	11297-11300	the	_
63-17	11301-11305	seed	_
63-18	11306-11309	ROI	_
63-19	11310-11313	and	_
63-20	11314-11318	each	_
63-21	11319-11324	other	_
63-22	11325-11335	individual	_
63-23	11336-11341	voxel	_
63-24	11342-11346	BOLD	_
63-25	11347-11348	.	_

64-1	11349-11352	CSF	_
64-2	11353-11354	,	_
64-3	11355-11359	grey	_
64-4	11360-11366	matter	_
64-5	11367-11368	,	_
64-6	11369-11374	white	_
64-7	11375-11381	matter	_
64-8	11382-11389	signals	_
64-9	11390-11393	and	_
64-10	11394-11400	motion	_
64-11	11401-11405	were	_
64-12	11406-11414	included	_
64-13	11415-11417	as	_
64-14	11418-11428	covariates	_
64-15	11429-11432	for	_
64-16	11433-11437	this	_
64-17	11438-11443	model	_
64-18	11444-11446	at	_
64-19	11447-11450	the	_
64-20	11451-11457	single	_
64-21	11458-11465	subject	_
64-22	11466-11471	level	_
64-23	11472-11473	.	_

65-1	11474-11479	These	_
65-2	11480-11492	correlations	_
65-3	11493-11497	were	_
65-4	11498-11508	calculated	_
65-5	11509-11519	separately	_
65-6	11520-11523	for	_
65-7	11524-11527	the	_
65-8	11528-11540	pre-infusion	_
65-9	11541-11544	and	_
65-10	11545-11558	post-infusion	_
65-11	11559-11564	scans	_
65-12	11565-11568	and	_
65-13	11569-11572	for	_
65-14	11573-11578	right	_
65-15	11579-11582	and	_
65-16	11583-11587	left	_
65-17	11588-11591	GPe	_
65-18	11592-11597	seeds	_
65-19	11598-11599	.	_

66-1	11600-11603	For	_
66-2	11604-11608	each	_
66-3	11609-11611	of	_
66-4	11612-11615	the	_
66-5	11616-11620	pre-	_
66-6	11621-11624	and	_
66-7	11625-11638	post-infusion	_
66-8	11639-11647	analyses	_
66-9	11648-11649	,	_
66-10	11650-11653	150	_
66-11	11654-11658	time	_
66-12	11659-11665	points	_
66-13	11666-11667	(	_
66-14	11668-11674	across	_
66-15	11675-11678	300	_
66-16	11679-11686	seconds	_
66-17	11687-11688	)	_
66-18	11689-11693	were	_
66-19	11694-11698	used	_
66-20	11699-11700	.	_

67-1	11701-11703	To	_
67-2	11704-11711	examine	_
67-3	11712-11717	group	_
67-4	11718-11723	level	_
67-5	11724-11731	effects	_
67-6	11732-11733	,	_
67-7	11734-11737	the	_
67-8	11738-11747	resulting	_
67-9	11748-11762	single-subject	_
67-10	11763-11775	connectivity	_
67-11	11776-11780	maps	_
67-12	11781-11785	were	_
67-13	11786-11790	used	_
67-14	11791-11793	as	_
67-15	11794-11799	input	_
67-16	11800-11803	for	_
67-17	11804-11810	second	_
67-18	11811-11816	level	_
67-19	11817-11825	analyses	_
67-20	11826-11828	in	_
67-21	11829-11830	a	_
67-22	11831-11838	general	_
67-23	11839-11845	linear	_
67-24	11846-11851	model	_
67-25	11852-11853	.	_

68-1	11854-11856	We	_
68-2	11857-11864	modeled	_
68-3	11865-11868	the	_
68-4	11869-11883	within-subject	_
68-5	11884-11890	effect	_
68-6	11891-11893	of	_
68-7	11894-11903	timepoint	_
68-8	11904-11905	(	_
68-9	11906-11910	i.e.	_
68-10	11911-11912	,	_
68-11	11913-11918	post-	_
68-12	11919-11925	versus	_
68-13	11926-11937	pre-alcohol	_
68-14	11938-11946	infusion	_
68-15	11947-11948	;	_
68-16	11949-11952	see	_
68-17	11953-11955	S1	_
68-18	11956-11960	File	_
68-19	11961-11962	,	_
68-20	11963-11965	S1	_
68-21	11966-11969	Fig	_
68-22	11970-11973	and	_
68-23	11974-11976	S1	_
68-24	11977-11982	Table	_
68-25	11983-11986	for	_
68-26	11987-11993	report	_
68-27	11994-11996	of	_
68-28	11997-12000	the	_
68-29	12001-12005	main	_
68-30	12006-12013	effects	_
68-31	12014-12016	of	_
68-32	12017-12024	alcohol	_
68-33	12025-12039	administration	_
68-34	12040-12041	)	_
68-35	12042-12045	and	_
68-36	12046-12061	between-subject	_
68-37	12062-12069	effects	_
68-38	12070-12072	of	_
68-39	12073-12084	impulsivity	_
68-40	12085-12086	(	_
68-41	12087-12093	BIS-11	_
68-42	12094-12095	,	_
68-43	12096-12102	UPPS-P	_
68-44	12103-12104	,	_
68-45	12105-12108	and	_
68-46	12109-12112	DDT	_
68-47	12113-12114	)	_
68-48	12115-12118	and	_
68-49	12119-12125	recent	_
68-50	12126-12134	drinking	_
68-51	12135-12144	behaviors	_
68-52	12145-12146	(	_
68-53	12147-12153	number	_
68-54	12154-12156	of	_
68-55	12157-12163	drinks	_
68-56	12164-12166	in	_
68-57	12167-12170	the	_
68-58	12171-12175	last	_
68-59	12176-12178	30	_
68-60	12179-12183	days	_
68-61	12184-12185	,	_
68-62	12186-12192	number	_
68-63	12193-12195	of	_
68-64	12196-12201	heavy	_
68-65	12202-12210	drinking	_
68-66	12211-12215	days	_
68-67	12216-12217	)	_
68-68	12218-12219	.	_

69-1	12220-12222	S1	_
69-2	12223-12228	Table	_
69-3	12229-12238	indicates	_
69-4	12239-12247	clusters	_
69-5	12248-12258	identified	_
69-6	12259-12261	as	_
69-7	12262-12269	showing	_
69-8	12270-12281	significant	_
69-9	12282-12289	changes	_
69-10	12290-12294	from	_
69-11	12295-12298	pre	_
69-12	12299-12301	to	_
69-13	12302-12306	post	_
69-14	12307-12314	alcohol	_
69-15	12315-12323	infusion	_
69-16	12324-12325	,	_
69-17	12326-12328	as	_
69-18	12329-12333	well	_
69-19	12334-12336	as	_
69-20	12337-12347	associated	_
69-21	12348-12358	statistics	_
69-22	12359-12360	.	_

70-1	12361-12364	For	_
70-2	12365-12368	the	_
70-3	12369-12382	seed-to-voxel	_
70-4	12383-12391	analysis	_
70-5	12392-12393	,	_
70-6	12394-12402	reported	_
70-7	12403-12411	clusters	_
70-8	12412-12420	survived	_
70-9	12421-12422	a	_
70-10	12423-12429	height	_
70-11	12430-12439	threshold	_
70-12	12440-12442	of	_
70-13	12443-12454	uncorrected	_
70-14	12455-12456	p	_
70-15	12457-12458	<	_
70-16	12459-12464	0.001	_
70-17	12465-12469	with	_
70-18	12470-12471	a	_
70-19	12472-12479	cluster	_
70-20	12480-12485	level	_
70-21	12486-12492	extent	_
70-22	12493-12502	threshold	_
70-23	12503-12505	of	_
70-24	12506-12519	FDR-corrected	_
70-25	12520-12521	p	_
70-26	12522-12523	<	_
70-27	12524-12528	0.05	_
70-28	12529-12530	.	_

71-1	12531-12533	In	_
71-2	12534-12538	Figs	_
71-3	12539-12542	3–5	_
71-4	12543-12544	,	_
71-5	12545-12550	these	_
71-6	12551-12559	clusters	_
71-7	12560-12563	are	_
71-8	12564-12569	shown	_
71-9	12570-12578	overlaid	_
71-10	12579-12581	on	_
71-11	12582-12592	structural	_
71-12	12593-12598	brain	_
71-13	12599-12607	cutaways	_
71-14	12608-12609	.	_

72-1	12610-12623	Corresponding	_
72-2	12624-12628	line	_
72-3	12629-12634	plots	_
72-4	12635-12638	are	_
72-5	12639-12643	only	_
72-6	12644-12647	for	_
72-7	12648-12654	visual	_
72-8	12655-12669	interpretation	_
72-9	12670-12672	of	_
72-10	12673-12678	these	_
72-11	12679-12686	effects	_
72-12	12687-12688	.	_

73-1	12689-12691	We	_
73-2	12692-12696	also	_
73-3	12697-12705	examined	_
73-4	12706-12709	sex	_
73-5	12710-12717	effects	_
73-6	12718-12720	on	_
73-7	12721-12736	alcohol-related	_
73-8	12737-12744	changes	_
73-9	12745-12747	in	_
73-10	12748-12751	GPe	_
73-11	12752-12764	connectivity	_
73-12	12765-12767	at	_
73-13	12768-12771	the	_
73-14	12772-12777	whole	_
73-15	12778-12783	brain	_
73-16	12784-12789	level	_
73-17	12790-12791	;	_
73-18	12792-12797	there	_
73-19	12798-12802	were	_
73-20	12803-12805	no	_
73-21	12806-12817	significant	_
73-22	12818-12829	differences	_
73-23	12830-12837	between	_
73-24	12838-12843	males	_
73-25	12844-12847	and	_
73-26	12848-12855	females	_
73-27	12856-12857	.	_

74-1	12858-12860	In	_
74-2	12861-12866	order	_
74-3	12867-12869	to	_
74-4	12870-12874	test	_
74-5	12875-12878	our	_
74-6	12879-12889	hypothesis	_
74-7	12890-12894	that	_
74-8	12895-12898	the	_
74-9	12899-12910	interaction	_
74-10	12911-12918	between	_
74-11	12919-12925	recent	_
74-12	12926-12934	drinking	_
74-13	12935-12944	behaviors	_
74-14	12945-12948	and	_
74-15	12949-12960	impulsivity	_
74-16	12961-12966	would	_
74-17	12967-12977	contribute	_
74-18	12978-12980	to	_
74-19	12981-12996	alcohol-induced	_
74-20	12997-13004	changes	_
74-21	13005-13007	in	_
74-22	13008-13011	GPe	_
74-23	13012-13022	functional	_
74-24	13023-13035	connectivity	_
74-25	13036-13037	,	_
74-26	13038-13040	we	_
74-27	13041-13050	extracted	_
74-28	13051-13063	ROI-to-voxel	_
74-29	13064-13075	correlation	_
74-30	13076-13082	values	_
74-31	13083-13090	between	_
74-32	13091-13094	the	_
74-33	13095-13100	seeds	_
74-34	13101-13104	and	_
74-35	13105-13116	significant	_
74-36	13117-13125	clusters	_
74-37	13126-13129	and	_
74-38	13130-13134	used	_
74-39	13135-13140	those	_
74-40	13141-13147	values	_
74-41	13148-13150	to	_
74-42	13151-13158	conduct	_
74-43	13159-13167	multiple	_
74-44	13168-13178	regression	_
74-45	13179-13187	analysis	_
74-46	13188-13190	in	_
74-47	13191-13200	R/RStudio	_
74-48	13201-13202	(	_
74-49	13203-13210	version	_
74-50	13211-13224	3.4.2/1.1.383	_
74-51	13225-13226	)	_
74-52	13227-13228	.	_

75-1	13229-13231	We	_
75-2	13232-13239	modeled	_
75-3	13240-13248	drinking	_
75-4	13249-13256	history	_
75-5	13257-13258	,	_
75-6	13259-13270	impulsivity	_
75-7	13271-13272	,	_
75-8	13273-13276	and	_
75-9	13277-13280	the	_
75-10	13281-13292	interaction	_
75-11	13293-13300	between	_
75-12	13301-13304	the	_
75-13	13305-13308	two	_
75-14	13309-13311	as	_
75-15	13312-13323	independent	_
75-16	13324-13333	variables	_
75-17	13334-13336	on	_
75-18	13337-13340	the	_
75-19	13341-13350	dependent	_
75-20	13351-13359	variable	_
75-21	13360-13362	of	_
75-22	13363-13369	change	_
75-23	13370-13372	in	_
75-24	13373-13376	GPe	_
75-25	13377-13389	connectivity	_
75-26	13390-13391	.	_

76-1	13392-13394	We	_
76-2	13395-13404	conducted	_
76-3	13405-13410	these	_
76-4	13411-13419	analyses	_
76-5	13420-13424	only	_
76-6	13425-13428	for	_
76-7	13429-13440	significant	_
76-8	13441-13449	clusters	_
76-9	13450-13460	identified	_
76-10	13461-13463	in	_
76-11	13464-13467	the	_
76-12	13468-13481	seed-to-voxel	_
76-13	13482-13490	analysis	_
76-14	13491-13492	,	_
76-15	13493-13496	and	_
76-16	13497-13501	only	_
76-17	13502-13505	for	_
76-18	13506-13509	the	_
76-19	13510-13521	significant	_
76-20	13522-13530	drinking	_
76-21	13531-13534	and	_
76-22	13535-13546	impulsivity	_
76-23	13547-13555	measures	_
76-24	13556-13557	.	_

77-1	13558-13561	For	_
77-2	13562-13565	the	_
77-3	13566-13574	drinking	_
77-4	13575-13583	measures	_
77-5	13584-13594	identified	_
77-6	13595-13597	in	_
77-7	13598-13602	that	_
77-8	13603-13616	seed-to-voxel	_
77-9	13617-13625	analysis	_
77-10	13626-13627	,	_
77-11	13628-13634	models	_
77-12	13635-13636	(	_
77-13	13637-13640	for	_
77-14	13641-13644	the	_
77-15	13645-13653	specific	_
77-16	13654-13665	significant	_
77-17	13666-13673	cluster	_
77-18	13674-13678	only	_
77-19	13679-13680	)	_
77-20	13681-13689	included	_
77-21	13690-13693	the	_
77-22	13694-13705	significant	_
77-23	13706-13714	drinking	_
77-24	13715-13723	variable	_
77-25	13724-13726	as	_
77-26	13727-13731	well	_
77-27	13732-13734	as	_
77-28	13735-13738	one	_
77-29	13739-13741	of	_
77-30	13742-13745	the	_
77-31	13746-13749	two	_
77-32	13750-13761	significant	_
77-33	13762-13773	impulsivity	_
77-34	13774-13783	variables	_
77-35	13784-13785	;	_
77-36	13786-13790	thus	_
77-37	13791-13792	,	_
77-38	13793-13794	2	_
77-39	13795-13806	regressions	_
77-40	13807-13810	per	_
77-41	13811-13818	cluster	_
77-42	13819-13823	were	_
77-43	13824-13827	run	_
77-44	13828-13829	.	_

78-1	13830-13839	Similarly	_
78-2	13840-13841	,	_
78-3	13842-13845	for	_
78-4	13846-13857	significant	_
78-5	13858-13869	impulsivity	_
78-6	13870-13878	measures	_
78-7	13879-13880	,	_
78-8	13881-13882	2	_
78-9	13883-13894	regressions	_
78-10	13895-13898	per	_
78-11	13899-13906	cluster	_
78-12	13907-13911	were	_
78-13	13912-13915	run	_
78-14	13916-13917	(	_
78-15	13918-13920	as	_
78-16	13921-13926	there	_
78-17	13927-13930	are	_
78-18	13931-13934	two	_
78-19	13935-13943	drinking	_
78-20	13944-13953	variables	_
78-21	13954-13955	)	_
78-22	13956-13957	.	_

79-1	13958-13962	This	_
79-2	13963-13971	resulted	_
79-3	13972-13974	in	_
79-4	13975-13976	a	_
79-5	13977-13982	total	_
79-6	13983-13985	of	_
79-7	13986-13988	20	_
79-8	13989-13994	tests	_
79-9	13995-13996	.	_

80-1	13997-13999	We	_
80-2	14000-14004	then	_
80-3	14005-14013	adjusted	_
80-4	14014-14017	the	_
80-5	14018-14025	omnibus	_
80-6	14026-14030	test	_
80-7	14031-14041	statistics	_
80-8	14042-14044	to	_
80-9	14045-14052	correct	_
80-10	14053-14056	for	_
80-11	14057-14065	multiple	_
80-12	14066-14077	comparisons	_
80-13	14078-14083	using	_
80-14	14084-14087	FDR	_
80-15	14088-14090	of	_
80-16	14091-14092	<	_
80-17	14093-14097	0.05	_
80-18	14098-14099	.	_

81-1	14100-14102	Of	_
81-2	14103-14108	those	_
81-3	14109-14120	regressions	_
81-4	14121-14122	,	_
81-5	14123-14127	only	_
81-6	14128-14133	those	_
81-7	14134-14138	with	_
81-8	14139-14150	significant	_
81-9	14151-14162	interaction	_
81-10	14163-14170	effects	_
81-11	14171-14174	are	_
81-12	14175-14183	reported	_
81-13	14184-14185	.	_

